Krystal Biotech is a biotechnology company focused on the development of gene therapies for patients living with rare diseases. Co.'s platform consists of a viral vector derived from the herpes simplex virus type 1 that Co. has improved for local and repeat gene transfer to epithelial cells. Co.'s product candidates include: Beremagene geperpavec, a topical gel containing its vector designed to deliver copies of the COL7A1 transgene for the treatment of dystrophic epidermolysis bullosa; and KB105, a topical gel containing Co.'s vector designed to deliver copies of the transglutaminase-1 (TGM1) transgene for the treatment of TGM1-deficient autosomal recessive congenital ichthyosis; The KRYS stock yearly return is shown above.
The yearly return on the KRYS stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the KRYS annual return calculation with any dividends reinvested as applicable (on ex-dates).
|